Maintaining radiochemical purity of [177Lu]Lu-DOTA-PSMA-617 for PRRT by reducing radiolysis

被引：0
作者：
Rory M. S. de Zanger
Ho Sze Chan
Wouter A. P. Breeman
Erik de Blois
机构：
[1] TNO,Nano
[2] AlfaRim Medical Holding BV,Instrumentation
[3] University Medical Center Rotterdam,Department of Internal Medicine
[4] University Medical Center Rotterdam,Department of Radiology and Nuclear Medicine
来源：
Journal of Radioanalytical and Nuclear Chemistry | 2019年 / 321卷
关键词：
PSMA; Radiochemical purity; RCP; Quenchers; Therapeutic dose; Radiolysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
[177Lu]Lu-DOTA-PSMA-617 for PRRT is subject to radiolysis and therefore loses receptor affinity. This will be detrimental for treatment efficacy. In this study optimal quencher(s) (combinations) are determined to maintain radiochemical purity with a downscaled model. Downscaled model in terms of activity, but at similar concentrations. DOTA-PSMA-617 was labeled with [177Lu]LuCl3 with different molar- and volume activities. Either methionine, ethanol or both showed superior effects on the stabilizing radiochemical purity of [177Lu]Lu-DOTA-PSMA-617. As a consequence, radiochemical purity of [177Lu]Lu-DOTA-PSMA-617 could be maintained by the addition of methionine and/or ethanol and downscaled model was proven and complementary.
引用
收藏
页码：285 / 291
页数：6
相关论文
共 122 条
  • [1] Pollock PA(2015)In 2124, half of all men can count on developing prostate cancer Curr Oncol 22 10-12
  • [2] Ludgate A(2019)(68)Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA < 0.5 ng/ml. Efficacy and impact on treatment strategy Eur J Nucl Med Mol Imaging 46 11-19
  • [3] Wassersug RJ(2019)(68)Ga-PSMA PET/CT for monitoring response to (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer Eur J Nucl Med Mol Imaging 46 1054-1062
  • [4] Farolfi A(2019)(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging? Wien Med Wochenschr 169 3-11
  • [5] Ceci F(2019)Re: [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Eur Urol 75 536-537
  • [6] Castellucci P(2019)(177)Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney J Nucl Med 12 2677-2685
  • [7] Graziani T(2012)Effectiveness of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC Curr Top Med Chem 35 839-849
  • [8] Siepe G(2008)Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides Nucl Med Biol 66 497-505
  • [9] Lambertini A(2008)Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors Appl Radiat Isot 2012 320198-1287
  • [10] Schiavina R(2012)Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience J Oncol 61 1279-34
12345678910